Acrivon Therapeutics, Inc. (ACRV) is up by 14 percent on Wednesday. The stock surged after the company announced that the U.S. Food and Drug Administration granted a special status to its ACR-368 OncoSignature assay, a multiplex immunofluorescence test designed to identify endometrial cancer patients who may benefit from ACR-368 treatment.
ACRV is currently trading at $6.77, up $0.86 from the previous close of $5.91. The stock has fluctuated today, reaching a high of $8.00 and a low of $5.83. Trading volume has soared to 0.67 million shares, significantly above the average of 0.05 million.
The stock remains within its 52-week range of $3.19 to $11.90. This recognition indicates that the FDA sees the test as having the potential to improve the treatment or diagnosis of life-threatening conditions.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.